Table 2.
DOAC plasma levels and characteristics per patient.
| Factor-Xa inhibitor | Dose | Indication | New/chronic users | DXM dose* | Days of DXM* | Age | Sex | Weight, kg | BMI | eGFR, ml/min* | Hepatic impairment† | CRP mg/l‡ | Other P-gp/CYP3A4 inducers/inhibitors | Factor-Xa trough level | Trough level § | Factor-Xa peak level | Peak level § |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apixaban | 2.5 mg bid | AF | New | 2 mg | 21 | 88 | M | 78 | 25.8 | 35 | No | 34 | No | 179 | High | 227 | High |
| Apixaban | 2.5 mg bid | AF | New | 6 mg | 6 | 95 | M | 66 | 21.1 | 19 | No | 131 | No | 36 | – | 69 | – |
| Apixaban | 2.5 mg bid | AF | New | 4 mg | 24 | 80 | M | 79 | 27.3 | 56 | No | 152 | No | 150 | – | 170 | – |
| Apixaban | 5 mg bid | AF | Chronic | 6 mg | 4 | 84 | F | 109 | 41 | 80 | No | 125 | No | 122 | – | 182 | – |
| Apixaban | 5 mg bid | VTE | New | 4 mg | 18 | 66 | M | 87 | 27.5 | 132 | No | 215 | No | 32 | – | 110 | – |
| Apixaban | 10 mg bid | VTE | New | 6 mg | 9 | 82 | M | 69 | 27 | 41 | No | 136 | No | 192 | – | 308 | – |
| Rivaroxaban | 10 mg od | Post AMI | Chronic | 6 mg | 7 | 78 | M | 78 | 26.1 | 82 | No | 132 | No | 41 | High | 125 | – |
| Rivaroxaban | 15 mg od | AF | New | 6 mg | 7 | 86 | F | 67 | 25.5 | 43 | No | 99 | No | 52 | – | 283 | – |
| Rivaroxaban | 20 mg od | AF | Chronic | 6 mg | 4 | 86 | M | 68 | 23.5 | 66 | No | 129 | No | 81 | – | 545 | High |
| Rivaroxaban | 20 mg od | AF | New | 6 mg | 6 | 83 | M | 90 | 27.2 | 89 | No | 89 | Remdesivir | 64 | – | 306 | – |
| Rivaroxaban | 20 mg od | AF | New | 6 mg | 5 | 74 | M | 110 | 32.8 | 75 | No | 100 | Remdesivir | 76 | – | 263 | – |
| Rivaroxaban | 20 mg od | AF | New | 6 mg | 6 | 71 | M | 116 | 35.8 | 90 | No | 152 | Remdesivir | 26 | – | 158 | Low |
| Rivaroxaban | 15 mg bid | VTE | New | 6 mg | 7 | 77 | F | 62 | 24.2 | 88 | Yes | 148 | Remdesivir | 79 | – | 256 | – |
| Edoxaban | 60 mg od | VTE | Chronic | 6 mg | 5 | 79 | M | 94 | 26.9 | 61 | No | 70 | No | 64 | High | 347 | High |
| Edoxaban | 60 mg od | VTE | New | 4 mg | 21 | 84 | F | 76 | 29 | 61 | No | 37 | No | 35 | – | 388 | High |
| Edoxaban | 60 mg od | VTE | New | 6 mg | 3 | 72 | M | 80 | 26.1 | 90 | Yes | 26 | No | 28 | – | 223 | – |
*At the time of factor-Xa measurement. No DXM dose indicates control patient, †At the time of factor-Xa measurement, defined as AST or ALT >3 times upper value. ‡ Measured on day of admission. § factor-Xa inhibitor plasma level above (High) or below (Low) expected range. Abbreviations DOAC: direct oral anticoagulants, DXM: dexamethasone; BMI: body mass index, eGFR: estimated glomerular filtration rate, P-gp: P-glycoprotein, bid: twice daily, od: once daily, AF: atrial fibrillation, VTE: venous thromboembolism, AMI: acute myocardial infarction, M: male, F: female.